| 產(chǎn)品描述： | Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway. |
| 靶點(diǎn)： |
IL-6;IL-1;STAT3;Lipoxygenase;STAT;Interleukin |
| 體內(nèi)研究： |
At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug |
| 參考文獻(xiàn)： |
1. Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61. 2. Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789. |
| 溶解性： |
Soluble in DMSO、1M NaOH |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.799 ml |
13.993 ml |
27.986 ml |
| 5 mM |
0.56 ml |
2.799 ml |
5.597 ml |
| 10 mM |
0.28 ml |
1.399 ml |
2.799 ml |
| 50 mM |
0.056 ml |
0.28 ml |
0.56 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
北京